BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for metabolic diseases by targeting the biology of human aging. Its lead program, BGE-102, is aimed at obesity and other metabolic conditions, with a stated goal of creating treatments that complement GLP-1 agonists and address unmet needs such as oral combination therapy. The company also uses longitudinal human aging datasets and a discovery platform to identify and validate novel therapeutic targets. BioAge has no approved products and does not yet generate product sales, so its business model currently depends on research collaboration revenue, external funding, and future clinical success.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueBGE-102 and related development work aimed at metabolic disease indications, including obesity.
Human aging data analytics used to identify and validate novel therapeutic targets.
Partnerships such as the Novartis and Lilly collaborations that fund discovery work and may generate milestones and royalties.
Internal and outsourced R&D activities supporting candidate advancement through early-stage testing.
Customers
BioAge does not currently sell approved medicines to end customers; instead, its near-term counterparties are pharmaceutical partners that fund or co-develop target discovery work. Novartis is a key collaboration partner under an agreement that provides upfront payments, research funding, and potential milestones tied to target discovery and validation. Lilly is another strategic partner in molecule discovery, reflecting a business model centered on partnering rather than direct commercialization. If BGE-102 or future candidates are approved, the company would then need to sell through physicians, hospitals, payors, and patients, either directly or via a commercialization partner.
Large pharma companies that pay for target discovery, validation, and optional licensing rights because BioAge's aging datasets can surface differentiated metabolic disease targets.
Potential licensees or co-marketing partners that would help fund late-stage development and market approved products if BioAge does not build its own sales force.
Physicians, hospitals, and reimbursement decision-makers that would influence adoption of any approved obesity or metabolic disease therapy.
End users for any approved therapy, especially obesity and related metabolic disease patients seeking differentiated treatment options.
Strategy
BioAge's strategy is to use human aging biology and longitudinal datasets to discover targets that can produce differentiated metabolic disease therapies. The company is prioritizing BGE-102 while also advancing additional platform targets and expanding the pipeline through internal discovery and partnerships. Collaboration with Novartis is central to monetizing the platform today, while Lilly and potential future partners broaden the target discovery engine and reduce single-asset dependence. Longer term, the company aims to move from discovery into clinical validation, regulatory approval, and, if successful, commercialization through either its own infrastructure or third-party partners.
The lead candidate is the most direct path to clinical value creation and future product revenue.
Collaborations such as Novartis and Lilly provide funding, validation, and optional downstream economics while reducing sole reliance on one program.
A wider pipeline improves the odds of finding commercially viable metabolic disease assets and diversifies scientific risk.
If a candidate is approved, the company needs either a partner or its own sales and marketing capabilities to capture value.
Geography
BioAge is headquartered in the United States and operates as a U.S.-based clinical-stage biotech company. Its main physical footprint includes office and lab space in Emeryville, California, which supports research and development activities. The company relies on third-party manufacturers located in China and India for preclinical and clinical supply, creating operational exposure to cross-border supply chains and geopolitical disruption. Because BioAge has no product sales today, geography matters mainly through where R&D is performed, where vendors are located, and where future regulatory and commercialization activities may occur.
Risks
BioAge faces the classic risks of a clinical-stage biotech: no approved products, no product revenue, and heavy dependence on successful clinical and regulatory outcomes. The company also relies on third-party CROs and CDMOs, including manufacturers in China and India, so supply disruptions, tariffs, geopolitical tensions, or quality failures could delay development or raise costs. Because it has never commercialized a product, it may struggle to build or outsource sales, reimbursement, and distribution capabilities if a candidate is approved. More broadly, the company is exposed to scientific risk, patent and IP disputes, trial execution risk, and the possibility that collaboration economics do not translate into durable value.
- Clinical development failureImpact: HighLikelihood: High
BGE-102 and future candidates may not demonstrate sufficient safety or efficacy to advance, which would eliminate the main path to product revenue.
Exposure: Lead asset and pipeline
- Funding and dilution riskImpact: HighLikelihood: High
The company remains loss-making and depends on capital markets and collaboration funding to sustain R&D.
Exposure: Corporate financing
- Third-party manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
The company relies on external manufacturers in China and India, so production issues, tariffs, or geopolitical events could delay trials or commercialization.
Exposure: Preclinical and clinical supply
- Commercialization capability gapImpact: MediumLikelihood: Low
BioAge has no sales or marketing infrastructure and no prior commercialization experience, making post-approval execution uncertain.
Exposure: Future approved products
- Intellectual property disputesImpact: MediumLikelihood: Low
Patent challenges or third-party infringement claims could require costly litigation or licensing and reduce economics from approved products.
Exposure: Platform and product candidates
Accounting
Judgemental itemsUpfront payments, research funding, and milestones must be recognized as work is performed, which affects the timing and volatility of reported revenue.
Impact: Novartis deferred revenue and quarterly collaboration revenue
Amounts received but not yet earned remain on the balance sheet and can reverse into revenue as obligations are satisfied.
Impact: Balance sheet liabilities and future revenue timing
Clinical and preclinical work is heavily outsourced, so accrual estimates affect expense recognition and operating loss timing.
Impact: Operating expenses and net loss
The Emeryville operating lease affects reported assets, liabilities, and occupancy expense over the lease term.
Impact: Balance sheet lease liability and G&A expense
Changes in fair value can create non-operating gains or losses that obscure underlying operating performance.
Impact: Other income (expense), net
Similar listed companies
Publicly listed companies with a comparable business focus.
BioVie Inc
BIVIW · Pharmaceutical Preparations
Bio-Path Holdings, Inc.
BPTH · Pharmaceutical Preparations
Passage BIO, Inc.
PASG · Biological Products, (No Diagnostic Substances)
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Last updated: 24/09/2026